For research use only. Not for therapeutic Use.
BCL6-IN-4 is a potent B-cell lymphoma 6 (BCL6) inhibitor with an IC50 of 97 nM. BCL6-IN-4 has anti-tumor activities[1].
BCL6-IN-4 (compound 25b) inhibits OCI-Ly1 and OCI-Ly3 cell lines growth with GI50 values of 2.8 μM and 4.2 μM, respectively[1].
| Catalog Number | I044491 |
| CAS Number | 2253879-65-9 |
| Synonyms | 5-[[5-chloro-2-(2,2,6,6-tetramethylmorpholin-4-yl)pyrimidin-4-yl]amino]-3-(3-hydroxy-3-methylbutyl)-1-methylbenzimidazol-2-one |
| Molecular Formula | C25H35ClN6O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C25H35ClN6O3/c1-23(2,34)10-11-32-19-12-16(8-9-18(19)30(7)22(32)33)28-20-17(26)13-27-21(29-20)31-14-24(3,4)35-25(5,6)15-31/h8-9,12-13,34H,10-11,14-15H2,1-7H3,(H,27,28,29) |
| InChIKey | BGCPLWWYPZAURQ-UHFFFAOYSA-N |
| SMILES | CC1(CN(CC(O1)(C)C)C2=NC=C(C(=N2)NC3=CC4=C(C=C3)N(C(=O)N4CCC(C)(C)O)C)Cl)C |
| Reference | [1]. Benjamin R Bellenie, et al. Achieving In Vivo Target Depletion through the Discovery and Optimization of Benzimidazolone BCL6 Degraders. J Med Chem. 2020 Apr 23;63(8):4047-4068. |
